Loading…

Adverse effects of antiretroviral therapy for HIV infection

Long-term remission of HIV-1 disease can be readily achieved by combinations of antiretroviral agents. The suppression of plasma viral loads to less than the limit of quantification of the most sensitive commercially available assays (i.e., less than 50 copies/mL) and the coincident improvement in C...

Full description

Saved in:
Bibliographic Details
Published in:Canadian Medical Association journal 2004-01, Vol.170 (2), p.229-238
Main Authors: Montessori, Valentina, Press, Natasha, Harris, Marianne, Akagi, Linda, Montaner, Julio S.G
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 238
container_issue 2
container_start_page 229
container_title Canadian Medical Association journal
container_volume 170
creator Montessori, Valentina
Press, Natasha
Harris, Marianne
Akagi, Linda
Montaner, Julio S.G
description Long-term remission of HIV-1 disease can be readily achieved by combinations of antiretroviral agents. The suppression of plasma viral loads to less than the limit of quantification of the most sensitive commercially available assays (i.e., less than 50 copies/mL) and the coincident improvement in CD4 T cell counts is associated with resolution of established opportunistic infections and a decrease in the risk of new opportunistic infections. However, prolonged treatment with combination regimens can be difficult to sustain because of problems with adherence and toxic effects. All antiretroviral drugs can have both short-term and long-term adverse events. The risk of specific side effects varies from drug to drug, from drug class to drug class, and from patient to patient. A better understanding of the adverse effects of antiretroviral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV-positive patients.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_315530</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>544099171</sourcerecordid><originalsourceid>FETCH-LOGICAL-h350t-8c9e968c4ee351cad2815ea63606fa1938da59b701be6160f88c90d34fd50a883</originalsourceid><addsrcrecordid>eNpdkF9LwzAUxYMobk6_ghQffCskTdKmiA9jqBsMfFFfQ9berBltM5N2Zd_eDOffpwv3_s69554TNCZMiDihSX6KxhhjETOG8xG68H6Dcehjdo5GhGWUMSrG6G5a7sB5iEBrKDofWR2ptjMOOmd3xqk66ipwaruPtHXRfPEWmfZAGtteojOtag9XxzpBr48PL7N5vHx-Wsymy7iiHHexKHLIU1EwAMpJocpEEA4qpSlOtSI5FaXi-SrDZAUpSbEWQYFLynTJsRKCTtD9595tv2qgLKDtgi-5daZRbi-tMvLvpDWVXNudpIRzioP-9qh39r0H38nG-ALqWrVgey9JljOeJIdDN__Aje1dG36TITcRrKYH6Pq3m28bX5n-nKvMuhpCktI3qq4DTuQwDCTDMpFJktMPdIyBGg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>204819368</pqid></control><display><type>article</type><title>Adverse effects of antiretroviral therapy for HIV infection</title><source>PubMed Central</source><creator>Montessori, Valentina ; Press, Natasha ; Harris, Marianne ; Akagi, Linda ; Montaner, Julio S.G</creator><creatorcontrib>Montessori, Valentina ; Press, Natasha ; Harris, Marianne ; Akagi, Linda ; Montaner, Julio S.G</creatorcontrib><description>Long-term remission of HIV-1 disease can be readily achieved by combinations of antiretroviral agents. The suppression of plasma viral loads to less than the limit of quantification of the most sensitive commercially available assays (i.e., less than 50 copies/mL) and the coincident improvement in CD4 T cell counts is associated with resolution of established opportunistic infections and a decrease in the risk of new opportunistic infections. However, prolonged treatment with combination regimens can be difficult to sustain because of problems with adherence and toxic effects. All antiretroviral drugs can have both short-term and long-term adverse events. The risk of specific side effects varies from drug to drug, from drug class to drug class, and from patient to patient. A better understanding of the adverse effects of antiretroviral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV-positive patients.</description><identifier>ISSN: 0008-4409</identifier><identifier>ISSN: 0820-3946</identifier><identifier>EISSN: 1488-2329</identifier><identifier>PMID: 14734438</identifier><identifier>CODEN: CMAJAX</identifier><language>eng</language><publisher>Canada: Can Med Assoc</publisher><subject>Anti-HIV Agents - adverse effects ; Anti-HIV Agents - therapeutic use ; Antiretroviral Therapy, Highly Active - adverse effects ; Antiretroviral Therapy, Highly Active - methods ; Chemical and Drug Induced Liver Injury ; Drug Therapy, Combination ; Drugs ; Female ; Follow-Up Studies ; HIV ; HIV Infections - diagnosis ; HIV Infections - drug therapy ; HIV Infections - mortality ; Human immunodeficiency virus ; Humans ; Hyperglycemia - chemically induced ; Hyperglycemia - epidemiology ; Hyperlipidemias - chemically induced ; Hyperlipidemias - epidemiology ; Incidence ; Lipodystrophy - chemically induced ; Lipodystrophy - epidemiology ; Liver Diseases - epidemiology ; Male ; Osteonecrosis - chemically induced ; Osteonecrosis - epidemiology ; Physiological aspects ; Randomized Controlled Trials as Topic ; Review ; Risk Assessment ; Skin Diseases - chemically induced ; Skin Diseases - epidemiology ; Survival Analysis ; Treatment</subject><ispartof>Canadian Medical Association journal, 2004-01, Vol.170 (2), p.229-238</ispartof><rights>Copyright Canadian Medical Association Jan 20, 2004</rights><rights>2004 Canadian Medical Association or its licensors</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC315530/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC315530/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14734438$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Montessori, Valentina</creatorcontrib><creatorcontrib>Press, Natasha</creatorcontrib><creatorcontrib>Harris, Marianne</creatorcontrib><creatorcontrib>Akagi, Linda</creatorcontrib><creatorcontrib>Montaner, Julio S.G</creatorcontrib><title>Adverse effects of antiretroviral therapy for HIV infection</title><title>Canadian Medical Association journal</title><addtitle>CMAJ</addtitle><description>Long-term remission of HIV-1 disease can be readily achieved by combinations of antiretroviral agents. The suppression of plasma viral loads to less than the limit of quantification of the most sensitive commercially available assays (i.e., less than 50 copies/mL) and the coincident improvement in CD4 T cell counts is associated with resolution of established opportunistic infections and a decrease in the risk of new opportunistic infections. However, prolonged treatment with combination regimens can be difficult to sustain because of problems with adherence and toxic effects. All antiretroviral drugs can have both short-term and long-term adverse events. The risk of specific side effects varies from drug to drug, from drug class to drug class, and from patient to patient. A better understanding of the adverse effects of antiretroviral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV-positive patients.</description><subject>Anti-HIV Agents - adverse effects</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral Therapy, Highly Active - adverse effects</subject><subject>Antiretroviral Therapy, Highly Active - methods</subject><subject>Chemical and Drug Induced Liver Injury</subject><subject>Drug Therapy, Combination</subject><subject>Drugs</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>HIV</subject><subject>HIV Infections - diagnosis</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - mortality</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Hyperglycemia - chemically induced</subject><subject>Hyperglycemia - epidemiology</subject><subject>Hyperlipidemias - chemically induced</subject><subject>Hyperlipidemias - epidemiology</subject><subject>Incidence</subject><subject>Lipodystrophy - chemically induced</subject><subject>Lipodystrophy - epidemiology</subject><subject>Liver Diseases - epidemiology</subject><subject>Male</subject><subject>Osteonecrosis - chemically induced</subject><subject>Osteonecrosis - epidemiology</subject><subject>Physiological aspects</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Review</subject><subject>Risk Assessment</subject><subject>Skin Diseases - chemically induced</subject><subject>Skin Diseases - epidemiology</subject><subject>Survival Analysis</subject><subject>Treatment</subject><issn>0008-4409</issn><issn>0820-3946</issn><issn>1488-2329</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpdkF9LwzAUxYMobk6_ghQffCskTdKmiA9jqBsMfFFfQ9berBltM5N2Zd_eDOffpwv3_s69554TNCZMiDihSX6KxhhjETOG8xG68H6Dcehjdo5GhGWUMSrG6G5a7sB5iEBrKDofWR2ptjMOOmd3xqk66ipwaruPtHXRfPEWmfZAGtteojOtag9XxzpBr48PL7N5vHx-Wsymy7iiHHexKHLIU1EwAMpJocpEEA4qpSlOtSI5FaXi-SrDZAUpSbEWQYFLynTJsRKCTtD9595tv2qgLKDtgi-5daZRbi-tMvLvpDWVXNudpIRzioP-9qh39r0H38nG-ALqWrVgey9JljOeJIdDN__Aje1dG36TITcRrKYH6Pq3m28bX5n-nKvMuhpCktI3qq4DTuQwDCTDMpFJktMPdIyBGg</recordid><startdate>20040120</startdate><enddate>20040120</enddate><creator>Montessori, Valentina</creator><creator>Press, Natasha</creator><creator>Harris, Marianne</creator><creator>Akagi, Linda</creator><creator>Montaner, Julio S.G</creator><general>Can Med Assoc</general><general>CMA Impact, Inc</general><general>Canadian Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M3G</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7T2</scope><scope>7U1</scope><scope>7U2</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20040120</creationdate><title>Adverse effects of antiretroviral therapy for HIV infection</title><author>Montessori, Valentina ; Press, Natasha ; Harris, Marianne ; Akagi, Linda ; Montaner, Julio S.G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h350t-8c9e968c4ee351cad2815ea63606fa1938da59b701be6160f88c90d34fd50a883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Anti-HIV Agents - adverse effects</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral Therapy, Highly Active - adverse effects</topic><topic>Antiretroviral Therapy, Highly Active - methods</topic><topic>Chemical and Drug Induced Liver Injury</topic><topic>Drug Therapy, Combination</topic><topic>Drugs</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>HIV</topic><topic>HIV Infections - diagnosis</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - mortality</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Hyperglycemia - chemically induced</topic><topic>Hyperglycemia - epidemiology</topic><topic>Hyperlipidemias - chemically induced</topic><topic>Hyperlipidemias - epidemiology</topic><topic>Incidence</topic><topic>Lipodystrophy - chemically induced</topic><topic>Lipodystrophy - epidemiology</topic><topic>Liver Diseases - epidemiology</topic><topic>Male</topic><topic>Osteonecrosis - chemically induced</topic><topic>Osteonecrosis - epidemiology</topic><topic>Physiological aspects</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Review</topic><topic>Risk Assessment</topic><topic>Skin Diseases - chemically induced</topic><topic>Skin Diseases - epidemiology</topic><topic>Survival Analysis</topic><topic>Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Montessori, Valentina</creatorcontrib><creatorcontrib>Press, Natasha</creatorcontrib><creatorcontrib>Harris, Marianne</creatorcontrib><creatorcontrib>Akagi, Linda</creatorcontrib><creatorcontrib>Montaner, Julio S.G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Canadian Business &amp; Current Affairs Database</collection><collection>Canadian Business &amp; Current Affairs Database (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest research library</collection><collection>ProQuest Science Journals</collection><collection>CBCA Reference &amp; Current Events</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Canadian Medical Association journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Montessori, Valentina</au><au>Press, Natasha</au><au>Harris, Marianne</au><au>Akagi, Linda</au><au>Montaner, Julio S.G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adverse effects of antiretroviral therapy for HIV infection</atitle><jtitle>Canadian Medical Association journal</jtitle><addtitle>CMAJ</addtitle><date>2004-01-20</date><risdate>2004</risdate><volume>170</volume><issue>2</issue><spage>229</spage><epage>238</epage><pages>229-238</pages><issn>0008-4409</issn><issn>0820-3946</issn><eissn>1488-2329</eissn><coden>CMAJAX</coden><abstract>Long-term remission of HIV-1 disease can be readily achieved by combinations of antiretroviral agents. The suppression of plasma viral loads to less than the limit of quantification of the most sensitive commercially available assays (i.e., less than 50 copies/mL) and the coincident improvement in CD4 T cell counts is associated with resolution of established opportunistic infections and a decrease in the risk of new opportunistic infections. However, prolonged treatment with combination regimens can be difficult to sustain because of problems with adherence and toxic effects. All antiretroviral drugs can have both short-term and long-term adverse events. The risk of specific side effects varies from drug to drug, from drug class to drug class, and from patient to patient. A better understanding of the adverse effects of antiretroviral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV-positive patients.</abstract><cop>Canada</cop><pub>Can Med Assoc</pub><pmid>14734438</pmid><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-4409
ispartof Canadian Medical Association journal, 2004-01, Vol.170 (2), p.229-238
issn 0008-4409
0820-3946
1488-2329
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_315530
source PubMed Central
subjects Anti-HIV Agents - adverse effects
Anti-HIV Agents - therapeutic use
Antiretroviral Therapy, Highly Active - adverse effects
Antiretroviral Therapy, Highly Active - methods
Chemical and Drug Induced Liver Injury
Drug Therapy, Combination
Drugs
Female
Follow-Up Studies
HIV
HIV Infections - diagnosis
HIV Infections - drug therapy
HIV Infections - mortality
Human immunodeficiency virus
Humans
Hyperglycemia - chemically induced
Hyperglycemia - epidemiology
Hyperlipidemias - chemically induced
Hyperlipidemias - epidemiology
Incidence
Lipodystrophy - chemically induced
Lipodystrophy - epidemiology
Liver Diseases - epidemiology
Male
Osteonecrosis - chemically induced
Osteonecrosis - epidemiology
Physiological aspects
Randomized Controlled Trials as Topic
Review
Risk Assessment
Skin Diseases - chemically induced
Skin Diseases - epidemiology
Survival Analysis
Treatment
title Adverse effects of antiretroviral therapy for HIV infection
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T04%3A45%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adverse%20effects%20of%20antiretroviral%20therapy%20for%20HIV%20infection&rft.jtitle=Canadian%20Medical%20Association%20journal&rft.au=Montessori,%20Valentina&rft.date=2004-01-20&rft.volume=170&rft.issue=2&rft.spage=229&rft.epage=238&rft.pages=229-238&rft.issn=0008-4409&rft.eissn=1488-2329&rft.coden=CMAJAX&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E544099171%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h350t-8c9e968c4ee351cad2815ea63606fa1938da59b701be6160f88c90d34fd50a883%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=204819368&rft_id=info:pmid/14734438&rfr_iscdi=true